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Background: Inflammatory dilated cardiomyopathy (iDCM) is a common debilitating disease with poor prognosis
that often leads to heart failure and may require heart transplantation. The aim of this study was to evaluate sera
and biopsy samples from chronic iDCM patients, and to investigate molecular mechanism associated with left
ventricular remodeling and disease progression in order to improve therapeutic intervention.
Methods: Patients were divided into inflammatory and non-inflammatory DCM groups according to the
immunohistochemical expression of inflammatory infiltrates markers: T-lymphocytes (CD3), active-memory T
lymphocyte (CD45Ro) and macrophages (CD68). The inflammation, apoptosis, necrosis and fibrosis were
investigated by ELISA, chemiluminescent, immunohistochemical and histological assays.
Results: The pro-inflammatory cytokine IL-6 was significantly elevated in iDCM sera (3.3 vs. 10.98 μg/ml; P < 0.05).
Sera levels of caspase-9, −8 and −3 had increased 6.24-, 3.1- and 3.62-fold, (P < 0.05) and only slightly (1.3-, 1.22- and
1.03-fold) in biopsies. Significant release of Hsp60 in sera (0.0419 vs. 0.36 ng/mg protein; P < 0.05) suggested a
mechanistic involvement of mitochondria in cardiomyocyte apoptosis. The significant MMP9/TIMP1 upregulation
in biopsies (0.1931 - 0.476, P < 0.05) and correlation with apoptosis markers show its involvement in initiation of cell
death and ECM degradation. A slight activation of the extrinsic apoptotic pathway and the release of hsTnT might
support the progression of chronic iDCM.
Conclusions: Data of this study show that significant increase of IL-6, MMP9/TIMP1 and caspases-9, −8, −3 in sera
corresponds to molecular mechanisms dominating in chronic iDCM myocardium. The initial apoptotic pathway
was more activated by the intramyocardial inflammation and might be associated with extrinsic apoptotic pathway
through the pro-apoptotic Bax. The activated intrinsic form of myocardial apoptosis, absence of necrosis and decreased
fibrosis are most typical characteristics of chronic iDCM. Clinical use of anti-inflammatory drugs together with specific
anti-apoptotic treatment might improve the efficiency of therapies against chronic iDCM before heart failure occurs.
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Inflammatory processes usually characterize myocarditis,
the progression of which leads to development of dilated
cardiomyopathy (DCM) causing heart failure and finally
to heart tissue destruction [1,2]. Dilated cardiomyopathy
(DCM) is a heart muscle disease which leads to the en-
largement of one or both ventricles and consequent sys-
tolic dysfunction. DCM is a consequence of persistent* Correspondence: d.bironaite@imcentras.lt
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pro-inflammatory, viral, oxidative, neuro-hormonal,
and other micro- or macro environmental factors [3].
Accumulating data showed an importance of inflam-
matory component in the development of DCM, indi-
cating a relation between myocarditis, autoimmunity
and DCM even if immunosuppressive therapy is not al-
ways effective [4,5]. Therefore, a better understanding
of the molecular mechanisms dominating in inflammatory
DCM (iDCM) is needed in order to improve treatment
and prevent further heart destruction.article distributed under the terms of the Creative Commons Attribution License
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expressed in the heart but are rapidly expressed in re-
sponse to cardiac injury [6]. In most cases increased in-
flammation is in most cases a natural response to injury,
helping to heal and recover damaged tissues, whereas
overwhelming inflammation aggravates the disease [7].
High levels of accumulated pro-inflammatory factors in-
duce various pathogenic effects, such as improper func-
tioning of the left ventricle, cardiomyocyte death and/or
fibrosis [8-10]. It was shown that inflammatory media-
tors, such as IL-6 and tumor necrosis factor - alpha
(TNF-α) can activate apoptotic Fas-Fas ligand pathway
in chronic heart failure [11]. Additionally, inflammatory
cytokines activate members of the matrix metallopro-
teinase (MMP) family, zinc-depended endopeptidases,
which participate in remodeling of ECM and fibrotic
processes [12]. It is agreed, that likewise to heart failure,
the main processes characterizing DCM are hyper-
trophy or loss/death of myocytes and interstitial fibrosis
[13]. Despite of that, not all previously mentioned fea-
tures fit to various forms of DCM. Therefore, in the
present study, we have investigated the level of inflam-
mation and subsequent induction of apoptosis, necrosis
and fibrosis in sera and biopsies of chronic iDCM pa-
tients with purpose to estimate which of previously
mentioned processes are mostly and firstly activated. A
more detailed estimation of molecular mechanisms will
allow more efficient use of therapeutic means to treat
chronic iDCM and thereby prevent further myocardium
destruction.
Methods
Inclusion and exclusion criteria
Study subjects were 32 consecutive patients (25 males, 7
females, mean age 43.14 ± 11.86 years), admitted to a
tertiary referral Centre with clinically diagnosed DCM.
All patients showed enlarged LV associated with signifi-
cantly impaired systolic function (LVEF less 45%) on
echocardiography in association with long duration of
heart failure symptoms. At enrolment, the average
duration of observed symptoms was 24–30 month. In
addition to clinical severity of heart failure according to
the New York Heart Association classification, heart
failure was also identified by determination of concen-
tration of brain natriuretic peptide (BNP) in sera.
Exclusion criteria: 1) Known causes of heart failure,
such as hypertension, significant coronary artery disease,
valvular heart diseases, although not relative mitral re-
gurgitation, endocrine diseases, significant renal diseases
or drug or alcohol abuse; 2) Acute myocarditis suspected
by clinical presentation and diagnostic tests (signs or
symptoms of systemic infections; elevated erythrocyte
sedimentation rate, reactive C protein level and TnT/
TnI, acute chest pain with ST/T wave changes such as:ST-segment elevation or depression and T-wave inver-
sions; new onset of non-specific ECG signs like: bundle
branch block, AV-block and/or ventricular arrhythmias;
regional wall motion abnormalities on echocardiography;
edema and/or LGE on CMR).
All patients signed written informed consent for car-
diac catheterization and endomyocardial biopsies (EMB),
which includes resulting analysis to elucidate a possible
origin of the myocardial and coronary artery diseases.
Inflammatory cardiomyopathy was defined as a cardio-
myopathy with decreased LVEF, increased LVEDD, and a
positive myocardial inflammation score according to the
Dallas criteria as well as criteria of the ESC/WHO
[14-16]. All patients were subdivided into two groups:
inflammation-positive (n = 22) and inflammation-negative
(n = 10) according to immunohistochemically proven up-
regulation of inflammatory infiltrate markers. CD3 (T
lymphocyte), CD45Ro (active-memory T lymphocyte) and
CD68 (macrophage) were determined immunohisto-
chemicaly by counting positively stained cells per mm2.
Immunohistochemical stainings (IHC) of collected sam-
ples revealed the significant amounts of inflammatory
cellular infiltrates (≥14 leucocytes/mm2 including up to
4 monocytes/macrophages/mm2 with the presence of
CD3 positive T-lymphocytes ≥7 cells/mm2) in the biopsy
samples (Figure 1). A cut off for inflammation samples
(diffuse, focal or confluent) and the presence or the ab-
sence of necrosis and fibrosis were determined as earlier
described [15].
Additional medical examinations
All patients were interviewed about their medical history
and underwent a careful physical examination, as well as
laboratory studies, including test of thyroid function,
serum electrolytes (sodium, potassium), hsCRP, glucose,
HbA1c, cholesterol, triglyceride, HDL, LDL, cardiac
enzymes (CK, CK-MB, AST), hsTnT, urea, creatinine,
uric acid, coagulation tests (PT, aPTT), blood count
(hemoglobin, haematocrit, RBC, WBC and platelet
count). Each patient underwent investigations such as
blood pressure on admission, ECG, echocardiography,
Holter monitoring and spiroergometry. The same basic
medical treatment scheme was applied to all patients.
Essential physical and laboratory data are shown in
Table 1.
Cardiac catheterization and endomyocardial biopsies
Before EMB, each patient underwent coronary angiog-
raphy to exclude coronary artery disease as well as
right heart catheterization to assess haemodynamic
parameters: mean pulmonary artery (PA) pressure, pul-
monary capillary wedge pressure (PCWP) and pulmon-
ary vascular resistance (PVR). Right ventricular EMB
was obtained using a flexible bioptome via the right
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Figure 1 (See legend on next page.)
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Figure 1 Immunocytochemistry of inflammatory infiltrates. (A). CD3 negative, (3 cell/mm2). (B). CD3 positive, (20 cell/mm2). (C). CD45Ro
negative, (3 cell/mm2). (D). CD45Ro positive, CD45Ro (17 cell/mm2). (E). CD68 negative, (5 cell/mm2). (F). CD68 positive, (20 cell/mm2). (G). Mean
of total expression of inflammatory infiltrates. Immunohistochemical illustrations are representative and obtained from one inflammatory-positive
and one inflammatory-negative patient. ELISA data are presented as means ± SE from al least three independent measurements. Data were
considered significant at **p < 0.01 and ***p < 0.001.
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by ultrasound. Biopsies were taken from the right
inter-ventricular septum from patients with confirmed
absence of ischemia and cardiovascular pathology
(stenosis and occlusion). Biopsy specimens were imme-
diately placed at −80°C and later processed for appro-
priate studies. At least three EMBs samples were
subjected to the conventional histological and immu-
nohistochemical evaluation, while two EMBs were
stored in a biobank as retained biosamples. Blood col-
lection tubes (8.5 ml) were used for serum sampling of
each patient at the same time as EMB.
Preparation of blood samples
Collected blood samples were placed in vacutainer tubes
without anticoagulants and kept at room temperature
for 30–45 min to allow clotting. Samples were centri-
fuged for 15 min at the manufacturer’s recommended
speed (1,000 - 2,000 RCF). The upper layer was carefullyTable 1 Baseline characteristics of patients
Variable Inflammation negative group
Total No. of pts. Value
Sex (male/female) 10 8 (80%) / 2 (20%
Age (years) 10 46.7 ± 5.87
NYHA
II 10 1 (10%)
III 10 7 (70%)
IV 10 2 (20%)
Cardiac parameters
LBBB (%) 10 3 (30%)
Permanent AF (%) 10 2 (20%)
LVEF (%) 10 24.10 ± 2.28
LVEDD (cm) 10 6.89 ± 0.17
LVEDDI (cm/m2) 10 3.68 ± 0.21
Mean Ao (mmHg) 10 92.00 ± 3.95
Mean RAP (mmHg) 10 16.22 ± 3.19
Mean PCWP (mmHg) 10 25.00 ± 2.79
Mean PAP (mmHg) 10 34.89 ± 4.33
CI (L/min/m2) 10 2.38 ± 0.33
Data are presented as the means ± SE. *Significant at 0.05 level. ¿Chi- square test. Abbr
branch block; AF – atrial fibrillation; LVEF - left ventricular ejection fraction; LVEDD – le
diameter index; Ao – aortic; RAP – right atrial pressure; PCWP – pulmonary capillary weaspired, checked for turbidity, aliquated into cryovials,
labeled and stored at −80°C. Before measurement, all
serum samples were thawed on ice, centrifuged at
12,000 g for 5 min and, if necessary, appropriately
diluted.
Biochemical assays of inflammatory infiltrates and cytokines
Inflammatory infiltrates were estimated on fixed, paraffin-
embedded material. For classification of biopsies, the
previously mentioned markers (Santa Cruz Biotechnol-
ogy, Inc.), CD3 (T lymphocytes), CD45Ro (active-
memory T lymphocytes) and CD68 (macrophages)
were applied. Positive cells were registered by an expe-
rienced pathologist and expressed as number of cells
per mm2.
The pro-inflammatory cytokines TNF-α, IL-6 and
IL-1β in serum samples were assayed by solid-
phase, chemoluminescent immunometric assays using
IMMULITE/Immulite 1000 systems (Immulite, Siemens)Inflammation positive group
Total No. of pts. Value p Value
) 22 17 (77%)/5 (33%) 0.863¿
22 42.36 ± 2.07 0.389
22 0 (0%) 0.132¿
22 15 (68%) 0.918¿
22 7 (32%) 0.491¿
22 5 (22.7%) 0.659¿
22 0 (0%) 0.000¿*
22 23.05 ± 1.35 0.678
22 6.89 ± 0.19 0.998
22 3.71 ± 0.09 0.847
22 86.06 ± 2.71 0.291
22 11.44 ± 1.74 0.164
22 23.45 ± 2.70 0.731
22 32.95 ± 3.24 0.734
22 2.2 ± 0.14 0.573
eviations: NYHA – New York Heart Association functional class; LBBB – left bundle
ft ventricular end-diastolic diameter; LVEDDI – left ventricular end-diastolic
dge pressure; PAP – pulmonary artery pressure; CI – cardiac index.
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(Catalog No: LKNFZ (50 tests), LKNF1 (100 tests); IL-6
(Catalog No: LK6PZ (50 tests), IL-1β (Catalog No:
LKL1Z (50 tests)).
Biochemical assays for apoptosis and necrosis
ELISA was used to assay endomyocardial biopsies and
serum samples. The following biomarkers were analyzed:
Bcl-2, caspase-9, caspase-8 (Novus Biologicals Europe,
Cambridge, UK); Bax (Elabscience Biotechnology Co.,
Ltd, China); caspase 3, MMP9, TIMP1, APO1/Fas/CD95,
FasL (Invitrogen, Paisley, UK) and HSP60 (AssayPro, Saint
Charles, Missouri, USA).
All collected serum samples were centrifuged at
12,000 g for 5 min, aliquated in 50 μl portions and
stored at −80°C. Before measurement, serum samples
were thawed on ice, appropriately diluted and analyzed
by ELISA.
Collected heart tissue biopsies were immediately
inserted into clean tubes and kept at −80°C. Before
measurement, tissue samples were lysed in 100 μl of
RIPA lysis buffer (Thermo Scientific Inc., USA), sup-
plemented with protease- and phosphatase mini-
inhibitor tablets, 1 mM PMSF, 1 mM Na2VO4 and
25 mM NaF according to the manufacturer’s sugges-
tion (Thermo Scientific Inc., USA). Biopsy samples
were sonicated at 10 mV for 2 × 5 s on ice by a
Bandelin Sonopuls sonicator, kept for 30 min on ice,
centrifuged at 12,000 g for 15 min, aliquoted and
stored at −80°C.
Amount of protein in serum and biopsy samples
were measured using a modified Lowry Protein Assay
kit according to the manufacturer’s recommendations
(Thermo scientific Inc., USA). Absorbance was mea-
sured with a spectrophotometer (Asys UVM 340 Mi-
croplate Reader UK - Biochrom Ltd.) set to 750 nm.
The exact protein concentration of each unknown
sample was estimated using bovine serum albumin
(BSA) as a standard. Total protein concentrations
were expressed as μg/ml. Final concentration of bio-
markers was expressed as ng/mg of protein or pg/mg
protein.
The myocardial injury marker, high-sensitivity tropo-
nin T (hsTnT), was measured in serum using an
Elecsys 2010 analyzer (Roche Diagnostics, Indianapo-
lis, Indiana) and expressed as pg/ml. Myocardial ne-
crosis was estimated and scored by a competent
pathologist on at least three independent routinely
stained (Haematoxylin and Eosin (H&E)) sections.
Normal myofibres had peripheral nuclei, intact sarco-
lema and non-fragmented nuclei. Pyknosis of muscle
fiber nuclei, edema, and beginning of leuco-diapedesis
from the capillaries suggested that the myocardial cells
had reached the stage of necrosis.Histochemical measurement of fibrosis in endomyocardial
biopsies
Tissues collected for histological analyzes were fixed in
10% neutral buffered formalin, and then paraffin-
embedded in a tissue processor. Total cardiac fibro-
sis (including interstitial and perivascular forms) was
assessed. Specimens were stained with Masson’s trichrome
connective tissue stain according to a standard protocol.
Keratin and normal muscle fibers stained red, whereas fi-
brotic areas stained blue. Digital images from the experi-
mental glass slides were obtained using ScanScope Digital
Slide Scanner (Aperio, Vista, CA) at a 20× magnification
and archived on a devoted Spectrum Server 11.1.0.751
(Aperio). Quality control of the scanned images and all
further analysis were performed using ImageScope
V11.1.2.760 (Aperio) and WebScope V11.1.0.756 (Aperio).
Digital analysis of the slides was done using a Colocali-
zation V9 algorithm that was run for the whole slides,
ignoring the number of tissue cross sections on it –
making the process fully automated. A colocalization
algorithm uses the deconvolution method to separate
the stains and classifies each pixel according to the num-
ber of stains present. For colocalization, the threshold
for each stained sample is specified for a required stain
(e.g. Masson’s trichrome) and the algorithm reports the
percentage of areas for each stain combination is de-
tected: 1, 2, 3, 1 + 2, 1 + 3, 2 + 3, 1 + 2 + 3 or none (up to
3 areas were analyzed). The algorithm also provides an
eight-color mark-up image for visualization of colocalized
stains. Summing up the stain combinations 3, 2 + 3 and
1 + 3 calculated the total percentage of cardiac fibrosis.
PCR assay
Intramyocardial viruses were estimated by PCR assay
[18]. Briefly, genomic DNA and total RNA were extracted
simultaneously using ZR-Duet™ DNA/RNA Miniprep kit
(Zymo Research, Irvine, CA, USA). RNA (1 μg) was re-
versely transcribed in 20 μl reaction volumes using ran-
dom hexamers and First Strand cDNA Synthesis Kit
(Thermo Fisher, Vilnius, Lithuania) according to the ven-
dor’s recommendations. Forward primers for the second
round of PCR were labeled with 6-carboxyfluorescein
(FAM) at the 5′ end. Final PCR products were 10-fold
diluted and analyzed by capillary electrophoresis on a
Genetic Analyzer 3130xl, using GeneScan™ 600 LIZ™ Size
Standard and Gene Mapper Software v4.1 (Applied Bio-
systems, Foster City, CA, USA) for sizing PCR fragments.
The following virus species were detected in the biopsies
of 16 patients: parvo virus B19 (n = 11), human herpes
virus type 6 (n = 4), hepatitis C virus (n = 1), Eppstein-Barr
virus (n = 1), entero virus (n = 1), and varicella zoster virus
(n = 1). The frequencies of detected viral genomes were
equal in each tested group (50%) and, therefore, it did not
influence the results.
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All statistical analyses were performed using the SPSS
package (version 19.0 for Windows; SPSS Inc., Chicago,
IL, USA) at not higher than 5% significance level. The
normality of the data distribution was tested by the
Shapiro-Wilk test. Significance of measurements was
tested by Student’s t test or the Wilcoxon–Mann–Whitney
rank sum non-parametric test. For comparative purposes
Pearson’s correlation coefficient was used.
Ethical approval
The study was approved by the local Lithuanian Bioethics
Committee (license No. 158200-09-382-l03; No. 158200-
382-PP1-23). All patients signed written informed consent
to include their data in the study for each investigational
procedure. The investigation conforms to the principles
outlined in the Declaration of Helsinki.
Results
Inflammatory markers in dilated cardiomyopathy
Here, we monitored the inflammatory process by detect-
ing expression of CD3, CD45Ro and CD68 in inflamma-
tory infiltrates by immunohistochemistry (Figure 1). In
addition, we determined levels of inflammatory cytokines
TNF-α, IL-6 and IL-1β in sera. Representative immuno-
histochemical micrographs show the increased and dif-
fused expression of CD3, CD45Ro and CD68 (Figure 1A,
B, C, D, E and F). Total expression of cytokines in infil-
trates from inflammatory-negative and -positive groups is
shown in Figure 1G. T-lymphocyte receptors (CD3) and
active memory T-lymphocytes (CD45Ro) were signifi-
cantly upregulated 2.38-fold (P < 0.001) and 2.1-fold
(P < 0.01), respectively (Figure 1G). Significant accession
of CD3 and CD45Ro in iDCM myocardium also suggests
increased myocardial micro-vascular permeability.
Our data showed upregulation of the specific and gen-
eral inflammatory markers interleukin-6 (IL-6) and C-
reactive protein (hsCRP), respectively, in iDCM serum
samples (3.45-fold, P < 0.05 and 2.76-fold) (Table 2).
Changes of tumor necrosis factor alpha (TNF-α) and
interleukin-1beta (IL-1β), also known as catabolin, were
not significant in the iDCM sera.
Changes of apoptotic and necrotic biomarkers in iDCM
samples
Data presented in Figure 2A show significant correlation
between CD3 and IL-6. Significant correlation of IL-6
and hsCRP with the mitochondrial chaperonic protein
Hsp60 and pro-apoptotic Bax in sera, respectively,
suggests that myocardial inflammation mostly affected
the integrity of mitochondrial membranes (Figure 2B
and C). Levels of the mitochondrial membrane stabiliz-
ing protein Hsp60 in inflammation-positive sera were
8.97-fold higher (P < 0.05). Changes of APO1/Fas/CD95(FasR), the main receptor of extrinsic apoptotic pathway,
and its ligand (FasL) in sera and biopsies were not sig-
nificant (Table 2).
Data presented in Figure 3A demonstrate statistically
significant (P < 0.05) increase of caspase-9, −8 and −3 in
sera with the most prominent expression of caspase-9.
Enhanced expression of the same caspases in endo-
myocardial biopsy samples (Figure 3B) was, however,
slight and insignificant. The upregulation of high sen-
sitivity troponin T (hsTnT), a major structural sarco-
meric protein of the heart and a marker of necrosis
and/or cardiomyocyte injury, in sera was not signifi-
cant (Table 2). However, the sarcomeric protein hsTnT
in iDCM sera strongly correlated with the levels of
caspases-8, Bax and caspase-3 in biopsies, suggesting
cardiomyocyte injury and caspase-regulated release of
hsTnT (Table 3).
The correlation analysis of apoptotic biomarkers in iDCM
sera and biopsies
Data in Figure 4A demonstrate that caspase-9, a serum
cysteine-aspartic acid specific protease, also named
apoptosis-initiating caspase, significantly correlated with
the general inflammatory marker C-reactive protein
(hsCRP) confirming the sensitivity of the intrinsic apop-
totic pathway to inflammation. In parallel, the significant
correlation between caspase-9 and MMP9 tells us that
caspase-9 might be either directly activated by the
MMP9 or, alternatively, through the other mediators of
the intrinsic apoptotic pathways, such as Bcl-2 and Bax
(Figure 4C and D; P < 0.05). Results presented in Figure 4E
and F show that levels of caspase-9 are strongly correlated
(P < 0.05) with the executing caspase-3 and extrinsic apop-
totic pathway-initiating caspase-8, suggesting the inter-
action between the intrinsic and extrinsic apoptotic
pathways. Furthermore, a significant correlation was ob-
served between caspase-8 and the APO1/Fas/CD95 levels
in iDCM sera (Figure 5A). Caspase-8 also significantly
correlated with the pro-apoptotic Bax and MMP9 con-
firming the intersection of extrinsic and intrinsic pathways
at mitochondrial level and caspase-8 activation by MMP9
(Figure 5B and C).
Next, we have investigated correlation of apoptotic
biomarkers in iDCM myocardium. Caspase-9 in heart
tissues, similarly to that in sera, significantly correlated
with pro-inflammatory cytokine IL-6, and caspase-8 in
myocardium correlated with Bax and caspase-3 (Table 3).
The executing caspase-3 also demonstrated significant
correlation with both the intrinsic (Bax, Bcl-2) and ex-
trinsic (APO1/Fas/CD95 and FasL) apoptotic pathways
(Table 3). Similarly to that in sera, members of both
apoptotic pathways (Bcl-2, APO1/Fas/CD95 and FasL)
in biopsies significantly correlated with MMP9 and its
inhibitor TIMP1 (Table 3).
Table 2 Summarized data of measured biomarkers
Variable Inflammation negative group Inflammation positive group
Total No. of pts. Value Total No. of pts. Value p Value
Markers of inflammation in serum
TNF-α (pg/mL) 8 7.9313 ± 0.5106 21 14.2819 ± 5.0280 0.223
IL-6 (pg/mL) 8 3.3938 ± 0.8554 21 11.4038 ± 3.3614 0.031*
IL-1β (pg/mL) 8 5.0000 ± 0.0000 21 4.7619 ± 0.2381 0.329
CRP (μg/mL) 8 7.6875 ± 5.0460 19 21.5563 ± 6.9633 0.066¡
Markers of apoptosis in serum
Bcl2 (ng/mg protein) 10 0.0288 ± 0.0288 22 0.0536 ± 0.0455 0.889¡
Bax (ng/mg protein) 10 2.152717 ± 0.24 22 2.3354 ± 0.1606 0.535
Caspase-9 (ng/mg protein) 10 0.012955 ± 0.0013 22 0.0808 ± 0.0283 0.038*
Caspase-8 (ng/mg protein) 10 0.001 ± 0.0001 22 0.0031 ± 0.0009 0.043*¡
Caspase-3 (ng/mg protein) 10 0.0029 ± 0.0022 22 0.0105 ± 0.0023 0.025*
APO1/Fas/CD95 (ng/mg protein) 10 0.0000 ± 0.0000 22 0.00004 ± 0.00004 0.857¡
FasL (ng/mg protein) 10 0.0000 ± 0.0000 22 0.0000 ± 0.0000 N.A.
HSP60 (ng/mg protein) 10 0.0419 ± 0.0253 22 0.3760 ± 0.1468 0.035*
Markers of apoptosis in biopsy
Bcl2 (ng/mg protein) 10 83.5523 ± 26.2936 21 63.8790 ± 17.2137 0.540
Bax (ng/mg protein) 10 5.6452 ± 2.6905 21 6.8873 ± 3.7924 0.724¡
Caspase-9 (ng/mg protein) 10 29.6575 ± 12.5969 21 38.7122 ± 9.6108 0.950¡
Caspase-8 (ng/mg protein) 10 0.9483 ± 0.1640 21 1.1611 ± 0.1962 0.413
Caspase-3 (ng/mg protein) 10 0.2503 ± 0.0773 21 0.2586 ± 0.0649 0.935
APO1/Fas/CD95 (ng/mg protein) 10 3.4651 ± 0.6568 21 4.1921 ± 0.6607 0.443
FasL (ng/mg protein) 10 4.5550 ± 1.3594 21 4.0588 ± 1.1083 0.780
HSP-60 (ng/mg protein) 10 24.1262 ± 6.9102 21 19.2656 ± 4.5617 0.565
Marker of heart tissue contraction in serum
hsTnT (pg/mL) 8 35.4988 ± 9.0908 20 66.4145 ± 26.9755 0.289
Markers of extracellular matrix degradation
in serum
MMP9 (ng/mg protein) 10 1.3867 ± 0.0674 22 1.5261 ± 0.0508 0.115
TIMP1 (ng/mg protein) 10 5.9610 ± 0.3597 22 6.1223 ± 0.1497 0.686
MMP9/TIMP1 10 0.2355 ± 0.0090 22 0.2511 ± 0.0086 0.223
Markers of extracellular matrix degradation
in biopsy
MMP9 (ng/mg protein) 10 2.3698 ± 1.1931 21 2.7630 ± 0.9394 0.798
TIMP1 (ng/mg protein) 10 9.4917 ± 1.7605 21 7.8056 ± 1.4029 0.462
MMP9/TIMP1 10 0.1931 ± 0.0729 21 0.4760 ± 0.1048 0.035*
Frequency of viral genome 5 50% 11 50%
BNP (pg/mL) 10 1277.8500 ± 428.5054 22 1603.2591 ± 276.3777 0.532
Data are presented as the means ± SE. *Significant at 0.05 level. ¡ Wilcoxon–Mann–Whitney rank sum nonparametric test. Abbreviations: TNF-α - tumor necrosis factor α;
IL-6 – interleukin-6; IL-1β – interleukin 1β; Bcl-2 – B-cell lymphoma 2 protein; Bax – Bcl-2–associated X protein; Hsp60 – heat shock protein 60; MMP9 – matrix
metalloproteinase 9; TIMP1 – tissue inhibitor of matrix metalloproteinase 1; TNF-a – tumor necrosis factor-alfa; IL-1β – interleukin 1 beta; IL-6 – interleukin 6;
hs TnT – high sensitivity troponin T; CRP – C-reactive protein, BNP- B-type natriuretic protein; N.A. – not available.
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The final experimental part was dedicated to investigate
the level of fibrosis in the EMB samples. Data in Figure 6A
and B show that the level of fibrosis (blue stain) ininflammatory-positive biopsies was slightly lower com-
pared to the inflammatory-negative ones. The quanti-
tative expression of fibrosis staining confirmed our
observation (Figure 6C). The exact roles of collagen I
Figure 2 Correlation between inflammatory and mitochondrial membrane destabilization markers. (A). Correlation between serum
inflammatory cytokine IL-6 and CD3. (B). Correlation between IL-6 and mitochondrial membrane stabilizing chaperone Hsp60 in serums. (C).
Correlation between C-reactive protein (CRP) and Bax in serums. Correlation analysis was done by the statistical SPPS programme. Correlation was
significant at a level of P <0.05. Linear regression line is presented within 95% confidence interval. Regression coefficients (R2) are shown in
the graphs.
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the absence of collagen I and III quantification algo-
rithm under polarized light. This part needs additional
investigations.
Discussion
Inflammatory cardiomyopathy is often defined by myo-
carditis in association with cardiac dysfunction and
inflammation as a main factor of interconnection
[15,19]. Long-term studies have shown that less than
15% of patients with acute myocarditis developed di-
lated cardiomyopathy [20]. It was also demonstrated
that patients with proved active myocarditis in biopsies
and idiopathic DCM had the same long-term outcome
(56% vs. 54%, respectively) [21]. Therefore, investiga-
tion of underlying basic molecular mechanisms and
their possible pharmacological modulation could im-
prove treatment of chronic iDCM.
Formerly the inflammatory markers were thought
to be only indicators of risk but not causal factors
[22]. However, it was shown that the pro-inflammatorycytokines, such as TNF-α, IL-6 and IL-1β, might act syn-
ergistically at both mRNR and protein levels by impairing
cardiac contraction [23,24]. Pro-inflammatory IL-6 has
been reported to be involved in the remodeling of
left ventricle after myocardial infarction and induced
heart failure leading to skeletal muscle atrophy and
heart disorders [25,26]. The molecular mechanisms
by which IL-6 affect myocardium can be related to a
negative ionotropic effect and upregulation of nitric
oxide synthase, downregulation of SERCA2, stimula-
tion of collagen synthesis to name a few [27-29].
The activation of molecular mechanism in heart usu-
ally depends on the origin, duration and intensity of
toxic stimuli.
Recently, a strong and direct influence of IL-6 was
shown on mitochondrial function: IL-6 inhibited adipo-
cyte mitochondrial membrane potential, ATP production
and increased intracellular ROS levels [30,31]. Similar
to IL-6, a general inflammatory biomarker C-reactive
protein (hsCRP) also correlated with poor DCM
prognosis, heart failure and mitochondrion-mediated
DC
BA
Figure 3 Levels of pro-caspases-9, −8, and −3 in iDCM samples. (A). Levels of caspases in iDCM serum samples. (B). Levels of caspases in
iDCM biopsies. (C). Histological estimation of necrosis in inflammation-negative EMB. (D). Histological estimation of necrosis in inflammation-positive
EMB. Images are representative from one EMB of each group. Data are presented as means ± SE from at least three independent measurements. Data
were considered significant at *P < 0.05.
Bironaite et al. BMC Cardiovascular Disorders  (2015) 15:26 Page 9 of 14myocyte apoptosis [32-34]. It was also shown that,
CRP contributes to IL-6 expression which is a
stronger prognostic predictor of heart failure than
CRP [35,36]. In agreement with previous observa-
tions, our data show significant upregulation of IL-6
in chronic iDCM sera and its significant correlation
with numbers of infiltrated T-lymphocytes (CD3)
and secreted intra-mitochondrial Hsp60 proteinTable 3 Correlation of apoptotic, necrotic and inflammatory b
Casp-9 in
biopsy
Casp-8 in
biopsy
Casp-3 in
biopsy
Bcl2 in
biopsy
Casp-8 in biopsy 0.303
Casp-3 in biopsy 0.063 0.436*
Bcl2 in biopsy −0.202 0.175 0.486*
FasR in biopsy −0.097 −0.074 0.526* 0.739**
FasL in biopsy −0.046 0.007 0.442* 0.835**
MMP9 in biopsy −0.229 0.024 0.419 0.764**
TIMP1 in biopsy −0.012 −0.205 0.213 0.517*
Bax in biopsy 0.283 0.584** 0.678** 0.056
IL-6 in serum 0.518* −0.016 −0.011 −0.262
hs TNT in serum 0.434 0.598** 0.563* −0.125
Two tailed significance: *P < 0.05; **P < 0.01. Significant correlations are in bold type
Abbreviations: Casp-3 – Caspase-3; Casp-8 – Caspase-8; Casp-9 – Caspase-9; IL-6 – In
ligand; MMP9 – matrix metalloproteinase 9; TIMP1 – tissue inhibitor of matrix meta
60; hsTnT – high sensitivity Troponin T.levels. The significant correlation of CRP with pro-
apoptotic Bax and strong upregulation of caspase-9 in
sera confirmed that inner apoptotic pathway is more
sensitive to inflammation compared to the extrinsic
one. Additionally, the absence of necrosis and insignifi-
cant upregulation of apoptosis markers in biopsies
suggest the beginning of cell death in chronic iDCM
myocardium.iomarkers in EMB
FasR in
biopsy
FasL in
biopsy
MMP9 in
biopsy
TIMP1 in
biopsy
Bax in
biopsy
IL-6 in
serum
0.907**
0.730** 0.824**
0.795** 0.722** 0.401
0.139 0.053 0.128 −0.127
−0.202 −0.154 −0.041 −0.227 0.131
−0.067 −0.165 −0.120 −0.249 0.954** 0.231
.
terleukin-6; Bcl-2 – B-cell lymphoma 2 protein; FasR—Fas receptor; FasL – Fas
lloproteinase 1; Bax – Bcl-2–associated X protein; Hsp60 – heat shock protein
Figure 4 Correlation of caspase-9 with biomolecules in serum samples. Caspase-9 correlated with: (A). C-reactive protein (CRP). (B). matrix
metalloproteinase-9 (MMP-9). (C). B-cell lymphoma 2 protein (Bcl-2). (D). Bcl-2–associated X protein (Bax). (E). Caspase-8. (F). Caspase-3. Correlation
analysis was done by the statistical SPPS programme. Linear regression line is presented within 95% confidence interval. Regression coefficients
(R2) and statistical significance (P < 0.05) are shown in the graphs.
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tween both apoptotic pathways strengthening toxic
effects in heart [37]. It was shown that the member
of the extrinsic apoptotic pathway pro-caspase-8
cleaves the BH3 domain-only protein Bid, which in
turn, activates Bax, stimulates its integration into
mitochondrial membranes and release of cytochrome
c [38,39]. In agreement with previous observations,
data of the present study show a significant correl-
ation between caspase-8 and Bax levels in iDCM sera,
suggesting that Bax can be one of the most important
intersection points between the intrinsic and extrinsicapoptotic pathways. However, the mediators of ex-
trinsic apoptotic pathway in iDCM samples had low
initial level and intensity of activation suggesting this
pathway being a supporter but not a main leader of
heart cell death. The other authors’ observations con-
firmed that the extrinsic apoptotic pathway might
have low impact on cardiomyocyte death in left ven-
tricular tissue [40].
The ECM is an important mediator between different
cell types within the myocardium supporting its struc-
tural network which can be degraded by proteolytic
enzymes matrix metalloproteinases (MMPs). In animal
Figure 5 Correlation between caspase-8 and biomolecules in serum samples. Correlation of caspase-8 with: (A). Fas receptor (APO1/
Fas/CD95). (B). Bcl-2–associated X protein (Bax). (C). Matrix metalloproteinase-9 (MMP-9). Correlation analysis was done using SPPS program.
Linear regression line is presented within 95% confidence interval. Coefficients of regression (R2) and statistical significance (P < 0.05) are
shown in the graphs.
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levels were related to the progression of left ventricular
dilation and dysfunction [41]. Similar to the intrinsic
apoptotic pathway, MMP-9 was also found to be sensi-
tive to inflammation and to participate in the pathogen-
esis of cardiomyopathy [42]. Additionally, it was shown
that chronic heart failure involves endothelial apoptosis
in response to MMP-9 activation [43]. Data of this study
showed that the MMP-9/TIMP1 ratio in iDCM biopsies
was significantly upregulated and significantly corre-
lated with the markers of both apoptotic pathways (Bcl-
2, Fas receptor and Fas ligand). These observations sug-
gest that upregulation of MMP-9/TIMP1 are more
related to the activation of apoptotic pathways than to
the stimulation of fibrosis. Parallelly, the significant correl-
ation between hsTnT and apoptotic proteins caspases-8,
Bax and caspase-3 also reveals hsTnT contribution to the
impairment of cardiomyocyte and/or contraction ability
by activation of pro-apoptotic signaling cascades.
Conclusions
The present study demonstrates that persistent myo-
cardial stressors increase T-lymphocytes in myocardiumof iDCM patients which correlates with the augmented se-
cretion of inflammatory cytokines, such as IL-6. Chronic
myocardial inflammation subsequently affects mitochon-
dria and induces significant release of Hsp60 and caspase-
9, −8 and −3, suggesting activation of both apoptotic path-
ways with stronger implication on the intrinsic pathway.
The pro-apoptotic Bax is an important intersection point
for the extrinsic- and intrinsic apoptotic pathways, block-
age of which might improve iDCM treatment. The signifi-
cant activation of MMP-9/TIMP1 was enough to support
apoptosis but not fibrosis.
Taken together, our study suggests that biomarkers se-
creted to the serum parallels intramyocardial processes
and, therefore, might be useful not only for the diagnosis
but also for detailed studies of the molecular mechanism
behind chronic iDCM. The observed absence of necrosis
and fibrosis in chronic iDCM shows that disease had still
not reached an end-stage and might be controlled by
anti-inflammatory and specific anti-apoptotic drugs.
Limitations
The main limitation of this study is that it contains a
relatively low number of iDCM patients. The study also
CB
A
Figure 6 Histopathological findings of fibrosis in right ventricular EMB. (A). Inflammation-negative EMB. (B). Inflammation-positive EMB.
(C). Quantitative expression of fibrosis. Micrographs show one representative picture from one patient of each group. Fibrosis is colored
blue. Magnification × 10.
Bironaite et al. BMC Cardiovascular Disorders  (2015) 15:26 Page 12 of 14lacks normal heart biopsies because of ethical reasons.
However, the main goal of this study was to investigate
the main processes, molecular mechanism and signaling
pathways dominating in chronic iDCM of unknownorigin. The collection of additional iDCM samples
continues and, hopefully, in the future we will be able
to understand more about iDCM diagnosis and its
treatment.
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